Efficacy and Safety Study of Maintenance Treatment With rhTPO in Thrombocytopenic Subjects With ITP
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01805648|
Recruitment Status : Unknown
Verified March 2013 by Yongqiang Zhao, Peking Union Medical College.
Recruitment status was: Recruiting
First Posted : March 6, 2013
Last Update Posted : March 6, 2013
|Condition or disease||Intervention/treatment||Phase|
|Thrombocytopenia Immune Thrombocytopenia Idiopathic Thrombocytopenic Purpura||Drug: rhTPO||Phase 3|
The eligible subjects with ITP firstly will receive a pre-treatment of rhTPO 300 IU/Kg once daily up to 14 days. The subjects with two consecutive platelet counts above 50×10^9/L in the pre-treatment period will begin to receive maintenance treatment of rhTPO 300 IU/Kg for 12 weeks. In the period of maintenance treatment, starting dosing interval of rhTPO is every other day followed by the interval adjustments for keeping platelet counts between 30 ×10^9/L～100 ×10^9/L. Subsequently, subjects will stop treatment of rhTPO and be followed up for 4 weeks after maintenance treatment.
Platelet count, bleeding and other symptoms will be evaluated before and after treatment.
Platelet transfusion will be administered to subjects with active bleeding symptoms.
Toxicity will be monitored continuously during the entire study. Safety will be assessed by adverse events and laboratory tests.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||120 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Multicenter, Single-Arm, Open Label Study Evaluating the Efficacy and Safety of Maintenance Treatment With Recombinant Human Thrombopoietin in Thrombocytopenic Subjects With Immune Thrombocytopenia|
|Study Start Date :||February 2011|
|Estimated Primary Completion Date :||August 2013|
|Estimated Study Completion Date :||December 2013|
Active investigational product
Subcutaneously dosing of rhTPO is based on screening weight. Subjects will be given rhTPO 300 IU/Kg once daily up to 14 days in the pre-treatment period . When two consecutive platelet counts is above 50×10^9/L, the subjects will be begin to receive maintenance treatment of rhTPO 300 IU/Kg. In the period of maintenance treatment, starting dosing interval of rhTPO is every other day followed by the interval adjustments for keeping platelet counts between 30×10^9/L～100×10^9/L.
- The effective rate of maintenance treatment (the platelet count continued to be over 30 × 10^9/L) [ Time Frame: up to 16 weeks per subject ]
- The effective rate of maintenance treatments adopting different frequency of administration [ Time Frame: up to 16 weeks per subject ]
- Number of subjects with Adverse Events as a Measure of Safety [ Time Frame: up to 18 weeks per subject ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01805648
|Peking Union Medical College Hospital||Recruiting|
|Contact: Shujie Wang, Dr. firstname.lastname@example.org|
|Principal Investigator: Yongqiang Zhao, Dr.|
|Sub-Investigator: Shujie Wang, Dr.|
|Principal Investigator:||Yongqiang Zhao, Dr.||Peking Union Medical College|